12/2
07:30 am
cero
CERo Therapeutics Announces Trading on OTCQB Market
High
Report
CERo Therapeutics Announces Trading on OTCQB Market
11/25
07:12 am
cero
Aggressive cancer warning signs revealed after JFK's granddaughter's diagnosis [FOX News]
Medium
Report
Aggressive cancer warning signs revealed after JFK's granddaughter's diagnosis [FOX News]
11/20
06:02 am
cero
CERo Therapeutics (NASDAQ:CERO) was downgraded by analysts at D Boral Capital from a "strong-buy" rating to a "hold" rating.
High
Report
CERo Therapeutics (NASDAQ:CERO) was downgraded by analysts at D Boral Capital from a "strong-buy" rating to a "hold" rating.
11/18
12:41 pm
cero
CERo Therapeutics (NASDAQ:CERO) had its "hold" rating reaffirmed by analysts at D. Boral Capital.
Low
Report
CERo Therapeutics (NASDAQ:CERO) had its "hold" rating reaffirmed by analysts at D. Boral Capital.
11/5
08:00 am
cero
CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing
Medium
Report
CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing
11/4
10:11 am
cero
CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response [Yahoo! Finance]
High
Report
CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response [Yahoo! Finance]
11/4
09:05 am
cero
CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response
High
Report
CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response
11/3
02:28 pm
cero
CERo Therapeutics (NASDAQ:CERO) had its "hold" rating reaffirmed by analysts at Maxim Group.
Medium
Report
CERo Therapeutics (NASDAQ:CERO) had its "hold" rating reaffirmed by analysts at Maxim Group.
11/3
08:00 am
cero
CERo Therapeutics Announces Listing on OTC Markets
High
Report
CERo Therapeutics Announces Listing on OTC Markets
10/22
08:34 am
cero
CERo Therapeutics (NASDAQ:CERO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.
Medium
Report
CERo Therapeutics (NASDAQ:CERO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.
10/21
08:15 am
cero
CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML
High
Report
CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML
10/15
08:30 am
cero
CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025
High
Report
CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025
10/13
10:56 am
cero
CERo Therapeutics (NASDAQ:CERO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.
Medium
Report
CERo Therapeutics (NASDAQ:CERO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.
10/13
08:55 am
cero
CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML [Yahoo! Finance]
Low
Report
CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML [Yahoo! Finance]
10/13
08:30 am
cero
CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML
Low
Report
CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML
9/23
08:07 am
cero
CERo Therapeutics (NASDAQ:CERO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.
Low
Report
CERo Therapeutics (NASDAQ:CERO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.
9/22
09:33 am
cero
CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort [Yahoo! Finance]
Low
Report
CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort [Yahoo! Finance]
9/22
09:15 am
cero
CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort
Neutral
Report
CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort
9/9
08:54 am
cero
CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041 [Yahoo! Finance]
Medium
Report
CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041 [Yahoo! Finance]
9/9
08:15 am
cero
CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041
Low
Report
CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041
9/8
08:45 am
cero
CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia
High
Report
CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia